reports
Patheon Announces Intent to Voluntarily Delist from the NYSE Subject t...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its intention to voluntarily delist its ordinary shares, par value €0.01 per share (the “Shares”), from the NYSE. The voluntary delisting is subject to and conditioned upon (1) the initial expiration of the tender offer at 5:00 p.m., New York City time, on August 2...
Patheon to Invest $45 Million, Expanding Capabilities to Support Conti...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. “As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customized solutions to meet their ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Patheon N.V. (NYSE:PTHN) stock prior to May 15, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Patheon to Thermo Fisher Scientific Inc. (NYSE:TMO) for $35 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/PTHN-Info-Request-Form-ma-5885 or contact J...
Patheon Reports Fiscal 2017 Second Quarter
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $941 million, compared to $875 million in the comparable fisc...
Patheon Completes Sterile Expansion Project at Greenville, NC Manufact...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suite which are compliant with regulatory authorities. The PDS Sui...
Patheon Achieved More Outsourced New Drug Approvals Than Any Other Pro...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, has been cited once again as capturing the most outsourced new drug approvals (NDAs) in the US than any other contract manufacturing organization (CMO) in 2016. NDAs are authorized by the U.S. Food and Drug Administration (FDA). The annual 2017 PharmSource CMO Scorecard underscores the company’s leadership position in the CMO sector highlighting the f...
Patheon Reports Fiscal 2017 First Quarter Results
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended January 31, 2017. First quarter 2017 revenue was $457 million, an increase of 13% compared to the first quarter of 2016. Adjusted EBITDA in the first quarter was $83 million, 40% higher than the prior-year period. Adjusted EBITDA margin as a percentage of revenue was 18%, representing a 350 basis point increase compared to the prio...
Patheon to Announce First Quarter Fiscal Year 2017 Financial Results o...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today announced that it will release financial results for the first fiscal quarter 2017 on Thursday, March 16, 2017 before the market opens. Patheon’s management – Jim Mullen, CEO; Michel Lagarde, President; and Stuart Grant, CFO, will host a conference call and webcast to discuss the results on Thursday, March 16, 2017 at 8:00 a.m. Eastern Daylight Time (EDT). The conference call web...
Patheon Named Supply Chain Resiliency Partner of the Year
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that the company was selected as the winner of the “Supply Chain Resiliency Partner of the Year” award by the Global Supply Chain Resiliency Council. The award was presented at RESILIENCE 2017, the Annual Global Supply Chain Resiliency Council Conference and Awards Gala on Wednesday, March 1, 2017, in Silicon Valley, CA. The a...
CORRECTING and REPLACING PHOTO Patheon Announces Completion of its Acq...
DURHAM, N.C.--(BUSINESS WIRE)-- Please replace the photo with the accompanying corrected photo. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170201005669/en/ Patheon adds 300,000 sq ft state-of-the-art manufacturing site in Florence, South Carolina, USA to its global network. (Photo: Business Wire) The release reads: PATHEON ANNOUNCES COMPLETION OF ITS ACQUISITION OF STATE-OF-THE-ART MANUFACTURING SITE Company Gains Additional API Capacity and Majo...
Patheon to Participate in the 35th Annual J.P. Morgan Healthcare Confe...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE:PTHN), a leading provider of pharmaceutical development and manufacturing services, today announced that Jim Mullen, Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Monday, January 9, 2017 in San Francisco, CA. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.patheon.com/events-and-presentations. An archived version of the remarks will also...
Patheon Reports Growth Across All Segments For Fourth Quarter; Provide...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE:PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the fourth quarter and fiscal year ended October 31, 2016. Fourth quarter 2016 revenue was $510 million, an increase of 10% compared to the fourth quarter of 2015. The increase in the company’s financial performance was driven by year-over-year growth in all three business segments despite temporary closings at three sites due to weather and power ou...
CORRECTING and REPLACING Patheon to Announce Fourth Quarter and Fiscal...
DURHAM, N.C.--(BUSINESS WIRE)-- Second paragraph, first sentence of release, the day of the call and webcast should be Tuesday, December 20 (instead of Wednesday, December 20). The corrected release reads: PATHEON TO ANNOUNCE FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS ON DECEMBER 20, 2016; COMPANY TO PROVIDE FISCAL 2017 OUTLOOK Patheon N.V. (NYSE:PTHN), a leading global provider of pharmaceutical development and manufacturing services, today announced that it will release financial results ...
ADDING MULTIMEDIA Patheon to Acquire State-of-the-Art Manufacturing Si...
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. ("Patheon" or the "company") (NYSE:PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has signed a definitive agreement to acquire a state-of-the-art active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina, from Roche Holdings, Inc., an indirect, wholly owned subsidiary of Roche Holding Ltd., which it will integrate into the Patheon network. This Smar...
Patheon to Participate in Jefferies Global Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE:PTHN) today announced it will participate in the Jefferies Global Healthcare Conference to be held November 16-17, 2016 in London, England. Patheon is scheduled to present on Wednesday, November 16, 2016 at 10:40 AM GMT (5:40 AM Eastern Standard Time). An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.patheon.com/events-and-presentations. An archived version of the remarks will also be available through the Company’s website...
Patheon Announces the Retirement of Stuart Grant
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE:PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today announced that its executive vice president and chief financial officer, Stuart Grant, plans to retire in 2017. Grant will remain in his current role until a successor has been appointed and a transition has been completed. The company has initiated a search to identify a replacement for Grant. This Smart News Release features multimedia....
Insider bought: A director bought 10,000 shares at 29.550USD and
A director at Patheon Nv bought 10,000 shares at 29.550USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Patheon to Participate in Morgan Stanley Global Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE:PTHN), today announced it will participate in the Morgan Stanley Global Healthcare Conference to be held September 12-14, 2016 in New York City. Patheon is scheduled to present on Tuesday, September 13, 2016 at 8:35 AM (Eastern Daylight Time). An audio webcast of the presentation will be available live. You can access the webcasts at: http://ir.patheon.com/events-and-presentations. An archived version of the remarks will also be available through the Company’s website for a l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.